alexa Minocycline in active rheumatoid arthritis. A double-blind, placebo-controlled trial.
Materials Science

Materials Science

Journal of Nanomedicine & Biotherapeutic Discovery

Author(s): Kloppenburg M, Breedveld FC, Terwiel JP, Mallee C, Dijkmans BA

Abstract Share this page

Abstract OBJECTIVE: To determine the efficacy of minocycline in the treatment of rheumatoid arthritis (RA). METHODS: Minocycline (maximal oral daily dose 200 mg) or placebo was administered in a 26-week, randomized, double-blind study to 80 patients with active RA, who were treated or had previously been treated with at least one disease-modifying antirheumatic drug. RESULTS: There were 15 premature discontinuations: 6 (5 taking minocycline) because of adverse effects, 8 (all taking placebo) because of lack of efficacy, and 1 (taking placebo) because of intercurrent illness. There was a statistically significant improvement in the minocycline group over the placebo group. There was a pronounced improvement in laboratory parameters of disease activity; however, improvement in clinical parameters was less impressive. The observed adverse effects attributable to minocycline were mainly gastrointestinal symptoms and dizziness. CONCLUSION: The results of the present study suggest that minocycline is beneficial and relatively safe in RA patients.
This article was published in Arthritis Rheum and referenced in Journal of Nanomedicine & Biotherapeutic Discovery

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version